Public company, workplace, funding, and market signals
ExcepGen is a San Francisco biotech developing the RNAx platform, an mRNA-encoded ‘shield’ protein approach designed to dampen overactive innate immune responses so RNA/DNA medicines and vaccines are more tolerable and effective. Public sources disagree on the founding year (2017 vs. 2018) and on total funding ($14M seed disclosed in the 2023 company release vs. about $19.3M in third-party company profiles).
Primary product
RNAx platform for RNA/DNA therapeutics and vaccines
Founded
2017
Headquarters
780 Bryant St., San Francisco, CA 94107, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
RNA therapeutics / genetic medicines
Offices
0 jobs at Excepgen
Check back later for new openings
Business model
Stage
Seed
Total raised
$19.3M
Latest round
Seed · Aug 2023
Latest amount
$4M
Leadership
Chief Executive Officer & Co-founder
Chief Scientific Officer & Co-founder
Chief Operating Officer
Director of Vaccines
Head of Research and Development
Investors
Curiosity-driven and collaborative, with an emphasis on creative discussion, cross-disciplinary problem solving, and an inventive-but-pragmatic mindset.
Compensation
No public salary bands, equity terms, or benefit package were listed on the careers page; open roles are routed through an external WorkHQ portal.
Differentiators
Technology
Customers
Competitors
Estimated revenue
USD 1M-$10M
Estimated monthly visits
1K
Traffic estimate as of Jul 2026
PubMed / npj Vaccines · Apr 2025
Shows ExcepGen’s RNAx platform can reduce reactogenicity from saRNA-LNP vaccines while preserving or improving immunogenicity; the paper lists ExcepGen employees as authors and notes pending patents and equity interests.
Longevity.Technology · Oct 2023
Reiterates the stealth exit, $14M total seed funding, and the RNAx mechanism; mentions VitaDAO and the company’s goal of expanding the reach of DNA/RNA-based medicines.
PR Newswire · Aug 2023
Company announcement of a $4M seed round led by RA Capital Management, bringing disclosed total seed funding to $14M and describing the RNAx shield-protein platform.
Fierce Biotech · Mar 2019
Early coverage of ExcepGen’s original protein-discovery platform and Y Combinator launch; noted an early partnership with AstraZeneca and a lean founding team.